

Iannone Robert
Form 3
April 23, 2018

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB
Number: 3235-0104
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting
Person *

Â Iannone Robert

(Last)

(First)

(Middle)

2. Date of Event Requiring
Statement

(Month/Day/Year)

04/12/2018

3. Issuer Name **and** Ticker or Trading Symbol
IMMUNOMEDICS INC [IMMU]

4. Relationship of Reporting
Person(s) to Issuer

5. If Amendment, Date Original
Filed(Month/Day/Year)

(Check all applicable)

____ Director ____ 10% Owner

☒ Officer ____ Other
(give title below) (specify below)

See Remarks

6. Individual or Joint/Group
Filing(Check Applicable Line)
☒ Form filed by One Reporting
Person
____ Form filed by More than One
Reporting Person

C/O IMMUNOMEDICS,
INC,Â 300 THE AMERICAN
ROAD

(Street)

MORRIS PLAINS,Â NJÂ 07950

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security
(Instr. 4)

2. Amount of Securities
Beneficially Owned
(Instr. 4)

3. Ownership
Form:
Direct (D)
or Indirect
(I)
(Instr. 5)

4. Nature of Indirect Beneficial
Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form displays a
currently valid OMB control number.**

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 4)

2. Date Exercisable and
Expiration Date
(Month/Day/Year)

Date
Exercisable

Expiration
Date

3. Title and Amount of
Securities Underlying
Derivative Security
(Instr. 4)

Title

Amount or
Number of

4. Conversion
or Exercise
Price of
Derivative
Security

5. Ownership
Form of
Derivative
Security:
Direct (D)

6. Nature of Indirect
Beneficial Ownership
(Instr. 5)

Edgar Filing: Iannone Robert - Form 3

				Shares		or Indirect (I) (Instr. 5)	
Stock Options (right to buy)	Â (1)	04/09/2025	Common Stock, par value \$0.01 per share	110,000	\$ 14.46	D	Â
Stock Options (right to buy)	Â (1)	04/09/2025	Common Stock, par value \$0.01 per share	70,000	\$ 14.46	D	Â
Stock Options (right to buy)	Â (2)(3)	04/09/2025	Common Stock, par value \$0.01 per share	140,000	\$ 14.46	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Iannone Robert C/O IMMUNOMEDICS, INC 300 THE AMERICAN ROAD MORRIS PLAINS, NJ 07950	Â	Â	Â See Remarks	Â

Signatures

/s/Robert Iannone 04/23/2018

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reporting person was granted stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options vest 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter.
- The reporting person was granted performance-based vesting stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options will vest (i) as to 70,000 shares (a) 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter through the fourth anniversary of the date of grant (each date a "Vesting Date") and (b) subject to Immunomedics, Inc. common stock achieving a fair market value of \$28.92 or higher based on the average closing price for the prior 15 consecutive trading days on such Vesting Date; and (ii) as to 70,000 shares (a) 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter through the fourth anniversary of the date of grant and (b) subject to Immunomedics, Inc. common stock achieving a fair market value of \$43.38 or higher based on the average closing price for the prior 15 consecutive trading days on such Vesting Date.
- (3) If the performance-based vesting criteria of the stock options is not attained on an applicable Vesting Date, and to the extent such performance-based vesting criteria is subsequently attained, the applicable tranche of stock options may vest on the date such criteria is met.

Â

Remarks:

Mr.Â IannoneÂ isÂ theÂ Issuer'sÂ ChiefÂ MedicalÂ Officer.Â TheÂ Issuer'sÂ BoardÂ ofÂ DirectorsÂ identifiedÂ Mr.Â IannoneÂ asÂ theÂ Issuer'sÂ ChiefÂ MedicalÂ Officer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.